Reflux When to See a Doctor: Causes, Diagnosis, and Treatment

What Causes Reflux?

Reflux occurs when stomach contents travel backward into the esophagus. The lower esophageal sphincter (LES), a ring of muscle at the junction of the esophagus and stomach, normally stays closed between swallows. When it relaxes at the wrong time or loses tone permanently, acid and bile escape upward, irritating esophageal tissue that lacks the protective mucus lining of the stomach.

The Lower Esophageal Sphincter

Transient LES relaxations (TLESRs) account for the majority of reflux episodes in patients without a hiatal hernia. Research published in Gastroenterology found that TLESRs triggered roughly 94% of reflux events in healthy volunteers compared with 64% in patients with more severe esophagitis, where a chronically low basal LES pressure became the dominant mechanism. Both pathways matter clinically because they respond differently to therapy.

Hiatal Hernia and Anatomical Factors

A hiatal hernia, present in up to 60% of patients over age 60, displaces the gastroesophageal junction above the diaphragm. A systematic review in Alimentary Pharmacology and Therapeutics confirmed that hiatal hernia size correlates with lower LES pressure and higher acid exposure time. Larger hernias also impair esophageal clearance, meaning each reflux episode takes longer to resolve.

Dietary and Lifestyle Triggers

Specific exposures reduce LES tone or increase gastric pressure:

• High-fat meals delay gastric emptying and increase the window for reflux.
• Caffeine and alcohol relax the LES directly.
• Chocolate and peppermint contain compounds that inhibit LES contraction.
• Tobacco smoke reduces salivary bicarbonate, the esophagus's natural acid buffer.
• Obesity, particularly central adiposity, raises intraabdominal pressure and is the single strongest modifiable risk factor for new-onset GERD.

A 2006 prospective cohort study in JAMA (N=10,545) found that a BMI of 35 or above was associated with an odds ratio of 3.3 for GERD symptoms compared with normal-weight individuals (Jacobson et al., JAMA 2006).

Medications That Worsen Reflux

Several common drugs reduce LES pressure or directly irritate the esophageal mucosa. These include calcium channel blockers (amlodipine, nifedipine), nitrates, benzodiazepines, tricyclic antidepressants, and nonsteroidal anti-inflammatory drugs (NSAIDs). Bisphosphonates such as alendronate can cause pill esophagitis if swallowed without adequate water or taken while lying down. Patients on these medications who develop new or worsening reflux symptoms should tell their prescribing clinician before self-treating.

Symptoms of Reflux: Typical and Atypical

Classic GERD presents as heartburn (a retrosternal burning sensation) and regurgitation (the effortless return of acid or food to the throat or mouth). Most patients recognize these symptoms readily. The problem is that reflux also produces a wide range of atypical symptoms that delay diagnosis by months or years.

Typical Symptoms

• Heartburn occurring 30-60 minutes after meals or when lying down
• Acid or bitter taste in the mouth (water brash)
• Chest discomfort that mimics cardiac pain

Atypical and Extraesophageal Symptoms

The ACG 2022 GERD Guidelines note that reflux should be considered in patients with chronic cough (lasting more than 8 weeks), laryngitis, hoarseness, dental erosion, and non-cardiac chest pain when cardiac causes have been excluded. Nighttime reflux is particularly associated with respiratory symptoms because the supine position eliminates gravity-assisted esophageal clearance and swallowing frequency drops during sleep, reducing salivary acid neutralization.

Approximately 10-20% of patients with confirmed GERD on pH monitoring report no heartburn at all. This is called silent reflux or laryngopharyngeal reflux (LPR) and is frequently under-diagnosed. A prospective study in the American Journal of Gastroenterology found that ambulatory pH testing identified abnormal acid exposure in 55% of patients with chronic laryngitis who had no typical heartburn.

When Should You Worry About Reflux?

Occasional heartburn after a large meal is not alarming. See a doctor promptly when any of the following alarm features appear alongside reflux symptoms.

Alarm Features Requiring Prompt Evaluation

| Alarm Feature | Why It Matters | |---|---| | Dysphagia (difficulty swallowing) | May signal stricture or esophageal cancer | | Odynophagia (painful swallowing) | Can indicate ulceration or infection | | Unintentional weight loss (>5% body weight in 6 months) | Associated with malignancy | | Hematemesis (vomiting blood) | Indicates possible bleeding ulcer or tear | | Melena (black, tarry stools) | Upper GI bleeding until proven otherwise | | Iron-deficiency anemia without clear cause | Chronic mucosal blood loss | | New onset after age 60 | Higher pretest probability of structural disease |

The ACG guideline states: "The presence of alarm symptoms should prompt endoscopic evaluation to exclude complications of GERD and other serious conditions including malignancy." Patients who meet any single criterion in that table should not wait for a two-week trial of OTC therapy.

Frequency and Duration Rules

Beyond alarm features, frequency matters. Symptoms occurring more than twice per week for four or more weeks meet the Montreal Definition of GERD (Vakil et al., American Journal of Gastroenterology 2006). The Montreal Definition is the internationally accepted standard and reads: "GERD is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications." If your symptoms fit this frequency criterion, a clinical evaluation is appropriate even without alarm features.

Age-Specific Considerations

Adults over 60 presenting with new-onset reflux symptoms deserve earlier endoscopy than younger patients because the prevalence of Barrett's esophagus and esophageal adenocarcinoma rises sharply with age. Men over 50 with chronic GERD (more than 5 years), obesity, and smoking history carry the highest risk for Barrett's. The ACG recommends a one-time screening endoscopy in patients with these combined risk factors.

How Is Reflux Diagnosed?

No single test is both perfectly sensitive and specific for GERD. Diagnosis is clinical in straightforward cases and investigative when symptoms are atypical, severe, or refractory.

Clinical Diagnosis and PPI Trial

A validated clinical diagnosis can be made when a patient has classic heartburn and regurgitation that responds to a therapeutic trial of a proton pump inhibitor (PPI). The ACG guidelines support an 8-week empirical PPI trial as a diagnostic and therapeutic first step in patients with typical symptoms and no alarm features. A response rate above 50% symptom improvement supports a GERD diagnosis with reasonable accuracy. Sensitivity of the PPI trial for GERD ranges from 71% to 86% depending on the population tested.

Upper Endoscopy (EGD)

Upper endoscopy is indicated when alarm features are present, when symptoms fail to respond to PPI therapy, or when Barrett's esophagus surveillance is required. The procedure takes 15-30 minutes under moderate sedation. Endoscopy can identify erosive esophagitis, peptic strictures, hiatal hernia, Barrett's metaplasia, or esophageal cancer. It does NOT rule out GERD in a normal-appearing esophagus, because up to 70% of GERD patients have non-erosive reflux disease (NERD) with no visible mucosal damage.

Ambulatory pH and Impedance-pH Monitoring

For patients with persistent symptoms despite PPI therapy or atypical presentations, 24-hour ambulatory pH monitoring or combined multichannel intraluminal impedance-pH (MII-pH) testing provides the most accurate acid exposure data. MII-pH detects both acidic and weakly acidic reflux events, which is especially useful for patients on PPI therapy where residual reflux may be non-acid. A DeMeester score above 14.7 or an acid exposure time above 4% of total monitoring time is considered abnormal.

Esophageal Manometry

High-resolution esophageal manometry measures LES pressure and esophageal body motility. It is not diagnostic for GERD itself but is required before anti-reflux surgery (fundoplication) to exclude major motility disorders such as achalasia, which can mimic GERD symptomatically. Performing fundoplication on a patient with undiagnosed achalasia causes significant harm.

How Is Reflux Treated?

Treatment follows a stepwise approach: lifestyle modification first, OTC or prescription medications next, and procedural or surgical options for refractory cases.

Step 1: Lifestyle Modifications

Evidence-based lifestyle changes for GERD include:

• Weight loss: A 10-15% reduction in body weight reduces acid exposure time significantly. The PROBE study found that women who lost more than 3.5 BMI units had a 40% reduction in GERD symptom frequency.
• Head-of-bed elevation: Elevating the head of the bed by 6-8 inches (using wedge pillows or bed risers) reduces nocturnal acid exposure. A controlled crossover trial (N=20) showed a 67% reduction in acid contact time with head-of-bed elevation versus flat sleeping.
• Meal timing: Avoiding food within 3 hours of bedtime limits postprandial acid secretion during the high-risk supine period.
• Elimination of triggers: Patients should trial removing high-fat meals, citrus, tomato-based foods, caffeine, and alcohol for 4 weeks to assess individual response.

Step 2: Over-the-Counter Medications

Antacids (calcium carbonate, magnesium hydroxide) neutralize acid within minutes but have no effect on acid secretion and provide relief lasting only 30-60 minutes. They are appropriate for intermittent, predictable symptoms.

H2-receptor antagonists (famotidine 10-20 mg, available OTC) reduce histamine-stimulated acid secretion. Onset is 30-45 minutes with duration of 6-10 hours. Tolerance can develop within 2 weeks of continuous use.

Proton pump inhibitors (omeprazole 20 mg, esomeprazole 20 mg, lansoprazole 15 mg, available OTC) block the H+/K+-ATPase pump irreversibly in active parietal cells, reducing acid secretion by 80-90% over 24 hours. They should be taken 30-60 minutes before the first meal of the day for maximum efficacy. A 14-day OTC course is appropriate for self-treatment; if symptoms recur after stopping, prescription evaluation is warranted.

Step 3: Prescription PPIs

Prescription-strength PPIs (omeprazole 40 mg, esomeprazole 40 mg, pantoprazole 40 mg, rabeprazole 20 mg) are the standard of care for confirmed erosive esophagitis. A meta-analysis in Annals of Internal Medicine (N=7,635) found that PPIs achieved mucosal healing in 83.6% of erosive esophagitis patients at 8 weeks compared with 51.9% for H2-blockers (P<0.001). After healing, most patients with grade C or D esophagitis require indefinite maintenance therapy to prevent relapse, which occurs in up to 80% within 6 months of stopping PPIs.

The HealthRX clinical team uses the following decision framework for PPI de-escalation in patients who have been on long-term therapy:

1. Confirm original diagnosis with pH testing off PPI if endoscopy was normal at baseline.
2. Optimize lifestyle modifications before reducing dose.
3. Step down from twice-daily to once-daily dosing over 4 weeks.
4. Trial every-other-day dosing for 4 weeks, then OTC H2-blocker as needed.
5. Re-escalate immediately if alarm symptoms appear.

Step 4: Add-On and Prescription-Only Options

Baclofen (5-20 mg three times daily), a GABA-B agonist, reduces TLESRs and is used off-label as an adjunct for patients with persistent regurgitation despite PPI therapy. A randomized controlled trial (N=30) found baclofen 20 mg reduced reflux episodes by 43% and regurgitation episodes by 58% compared with placebo.

Sucralfate forms a cytoprotective barrier over ulcerated mucosa and may be useful in pill esophagitis or during pregnancy, where PPI use requires specialist guidance.

Alginate-based formulations (e.g., Gaviscon Advance) form a gel raft on top of stomach contents, physically blocking reflux. A Cochrane review found alginates superior to antacids for heartburn relief in head-to-head trials.

Step 5: Surgical and Endoscopic Options

Laparoscopic Nissen fundoplication remains the gold-standard surgical option for GERD. Candidates include patients who respond to PPIs but prefer not to take lifelong medication, patients with large hiatal hernias, and those with volume regurgitation not controlled by acid suppression alone. The REFLUX trial (N=810, BMJ 2008) showed that at 12 months, 62% of surgical patients reported satisfactory symptom control versus 45% of medically managed patients, though surgical complications occurred in 5% of patients.

Transoral incisionless fundoplication (TIF) is a less-invasive endoscopic option for patients with small hernias (<2 cm) and a preference for minimally invasive intervention. Long-term data beyond 5 years remain limited.

LINX device (magnetic sphincter augmentation) is a ring of magnetic titanium beads implanted laparoscopically around the LES. FDA-approved in 2012, it restores the LES barrier without altering gastric anatomy. A 5-year follow-up study showed 85% of patients achieved clinically meaningful improvement in GERD health-related quality of life scores, and 88% eliminated or reduced PPI use.

Barrett's Esophagus and Cancer Risk

Barrett's esophagus is the replacement of normal squamous esophageal epithelium with intestinal-type columnar epithelium, a change driven by chronic acid exposure. It is found in 10-15% of patients undergoing endoscopy for chronic GERD symptoms.

Who Should Be Screened?

The ACG recommends screening endoscopy in men with chronic GERD (more than 5 years) who have two or more additional risk factors: age over 50, white race, central obesity (waist circumference above 102 cm), current or past smoking, or a first-degree relative with Barrett's esophagus or esophageal adenocarcinoma. Women carry a three to four times lower risk of developing Barrett's than men with equivalent reflux severity.

Progression Risk

The annual risk of Barrett's esophagus progressing to esophageal adenocarcinoma is approximately 0.3% per year in patients without dysplasia. That number rises to 0.7% per year for low-grade dysplasia and exceeds 7% per year for confirmed high-grade dysplasia. A large population-based cohort study from Denmark (N=11,028, NEJM 2011) confirmed these progression rates and found that the absolute cancer risk in Barrett's patients without dysplasia was 1 in 300 per year, lower than earlier estimates.

Endoscopic eradication therapy (radiofrequency ablation, endoscopic mucosal resection) is indicated for confirmed dysplastic Barrett's esophagus and has largely replaced esophagectomy for high-grade dysplasia in otherwise healthy patients.

Special Populations

Reflux During Pregnancy

GERD affects up to 80% of pregnant women, peaking in the third trimester when uterine enlargement increases intraabdominal pressure and progesterone relaxes the LES. Calcium carbonate antacids and sucralfate are considered first-line because they are not systemically absorbed. Famotidine carries an FDA Pregnancy Category B rating and may be used when antacids fail. PPI use during pregnancy has been studied extensively. A 2010 meta-analysis in Alimentary Pharmacology and Therapeutics (N=134,940 pregnancies) found no significant increase in major congenital malformations with first-trimester PPI exposure, though most guidelines still recommend reserving PPIs for refractory cases.

Reflux in Older Adults

Older adults are more likely to have atypical presentations, larger hiatal hernias, and impaired esophageal motility. Polypharmacy interactions are common. PPI therapy in patients over 65 carries a modestly increased risk of Clostridioides difficile infection (relative risk approximately 1.7) and hypomagnesemia with long-term use. Bone density monitoring may be appropriate in older patients on continuous PPI therapy exceeding one year, as PPIs have been associated with a 22-31% increased fracture risk in observational data, though causality remains debated.

Pediatric Reflux

Physiologic reflux (spitting up) is near-universal in infants under 12 months and resolves spontaneously in 95% by age 12-18 months. Pediatric GERD requiring treatment is defined by reflux causing poor weight gain, feeding aversion, recurrent aspiration, or apparent life-threatening events. PPIs are approved for use in children down to 1 year of age (omeprazole) and 1 year of age (esomeprazole granules). Parents concerned about infant reflux should speak with a pediatrician before starting any medication.

What to Expect at Your Doctor's Visit

Arriving prepared saves time and leads to better care. Bring a symptom diary covering at least two weeks, noting frequency, timing in relation to meals, and any triggers you have identified. List all medications including OTC antacids, NSAIDs, and supplements. Tell your clinician whether you have ever had an upper endoscopy, what it showed, and whether you have a family history of esophageal or gastric cancer.

Your doctor will likely ask about alarm symptoms specifically. If none are present and you have classic symptoms, expect an empirical 8-week PPI trial as the first step. If symptoms resolve completely on PPI therapy, confirm a diagnosis of GERD and discuss long-term management. Incomplete response or rapid relapse after stopping PPIs warrants further investigation with pH monitoring or endoscopy.